EDOC:LSE:LSE-Global X Telemedicine & Digital Health ETF A (USD)

ETF | Others |

Last Closing

USD 7.883

Change

-0.13 (-1.60)%

Market Cap

USD 3.93M

Volume

201.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-1.75 (-0.94%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-3.13 (-2.62%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.02 (-0.12%)

USD 572.76B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.12 (+0.87%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.45 (+0.63%)

USD 266.08B
0QZO:LSE 0QZO

-1.75 (-1.83%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.04 (-0.13%)

USD 208.06B
0QZ3:LSE Qualcomm Inc.

-1.75 (-1.04%)

USD 202.26B
0R24:LSE Intel Corp.

-0.81 (-3.45%)

USD 196.14B

ETFs Containing EDOC:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.97% 12% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.97% 12% F 26% F
Trailing 12 Months  
Capital Gain 10.41% 35% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.41% 33% F 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.94% N/A N/A 14% F
Dividend Return -9.94% N/A N/A 13% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.83% N/A N/A 77% C+
Risk Adjusted Return -91.82% N/A N/A 6% D-
Market Capitalization 3.93M 17% F 9% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.